Dogwood Therapeutics, Inc. Common Stock (DWTX)

• Market cap: $4.2M
• 1 day: 68.45%
• 5 days: 36.36%
• 1 month: 15.81%
• 3 months: -20.25%
• 6 months: 0.96%
• Year to date: 25.50%
• 1 year: 0.96%
• 5 years: 0.96%
• 10 years: 0.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 4

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0% more funds holding

Funds holding: 24 [Q2] → 24 (+0) [Q3]

16% less capital invested

Capital invested by funds: $215K [Q2] → $180K (-$34.8K) [Q3]